The state of California currently has 210 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Magnetic Resonance Imaging in Radiotherapy for Breast Cancer
NCT05902507
Recruiting
This is a single-center, prospective pilot study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatment (RT) for breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: Breast Cancer
Register for Updates
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
NCT04072952
Recruiting
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/02/2023
Locations: Clinical Trial Site, Palo Alto, California +2 locations
Conditions: Breast Cancer
Register for Updates
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
NCT04756765
Recruiting
This purpose of this study is to test if talazoparib is safe and evaluate its response to advanced breast cancer associated with mutation of gene called PALB.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2023
Locations: Stanford University, Stanford, California
Conditions: Breast Cancer, Advanced Breast Cancer
Register for Updates
Impact of Topical Tranexamic Acid in Breast Reconstruction
NCT05807074
Recruiting
Improvement in bleeding and bruising has been described by using both intravenous and topical off-label applications of Tranexamic Acid (TXA) in many surgical fields. This trial tests how well applying tranexamic acid (TXA) to the surface of the surgical site (topically) works to reduce post-operative bleeding (hematomas) and fluid collections (seromas) in women undergoing surgery to remove both breasts (bilateral mastectomy) immediately followed by surgery to rebuild the breast (reconstruction)... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: Breast Cancer
Register for Updates
Magnetic Resonance Imaging of Breast Cancer
NCT01035112
Recruiting
To compare magnetic resonance imaging (MRI) with more well established diagnostic imaging techniques to determine which method best finds and defines breast cancer.
Gender:
Female
Ages:
21 years and above
Trial Updated:
03/23/2023
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Breast Cancer, Breast Cancer Non-invasive Breast Cancer
Register for Updates
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
All
Ages:
All
Trial Updated:
03/20/2023
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California +1 locations
Conditions: Breast Cancer
Register for Updates
Intraoperative Use of ClearEdge Device in Breast Conserving Surgery
NCT05456373
Recruiting
Multi center, pivotal prospective, randomized clinical trial The proposed randomized controlled study will evaluate the benefits of adding the ClearEdge imaging device to the Standard of Care (SoC) of margins assessment in breast conserving surgeries. The study will assess whether there is an improvement in the detection of DCIS or invasive cancer involved margins by measuring whether removal at the time of primary surgical treatment can reduce the need for repeat surgeries as compared to the S... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/20/2023
Locations: UCSF Medical Center at Mission Bay, San Francisco, California
Conditions: Breast Cancer
Register for Updates
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643
Recruiting
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: Arrowhead Regional Medical Center, Colton, California
Conditions: HER2-negative Breast Cancer
Register for Updates
Perioperative Mindfulness Proposal
NCT04049214
Recruiting
The purpose of this study is to determine if a regular meditation and breath work practice started before surgery and continued through post-surgical recovery can improve anxiety and pain related to breast cancer and its treatment.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/27/2023
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Breast Cancer, DCIS
Register for Updates
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT05190978
Recruiting
Surgical mesh products, particularly acellular dermal matrices (ADM), are now used by the majority of plastic surgeons to assist with the nearly 100,000 prosthetic breast reconstruction procedures in the United States, despite never being approved by Food and Drug Administration (FDA) for this indication. As surgeons transition to placing breast implants above the chest muscle (pre-pectoral), there has been an increasing reliance on these often expensive mesh products without robust evidence to... Read More
Gender:
Female
Ages:
Between 22 years and 75 years
Trial Updated:
02/21/2023
Locations: University of California Los Angeles, Los Angeles, California
Conditions: Breast Cancer, Breast Implant; Complications, Infection or Inflammation
Register for Updates
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT04913337
Recruiting
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: University of Southern California, Los Angeles, California +2 locations
Conditions: Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer
Register for Updates
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
NCT05453825
Recruiting
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: Cohort A: CRC Cohort B: Gastric and GEJ cancer Cohort C: TNBC Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2023
Locations: Keck Medicine of USC, Los Angeles, California
Conditions: Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Register for Updates